• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel?

作者信息

Ferreira Leonardo M R, Muller Yannick D

机构信息

Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, United States.

Hollings Cancer Center, Medical University of South Carolina, Charleston, SC, United States.

出版信息

Front Immunol. 2021 Nov 17;12:766220. doi: 10.3389/fimmu.2021.766220. eCollection 2021.

DOI:10.3389/fimmu.2021.766220
PMID:34868017
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8635711/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fd2/8635711/c2ddea7adb69/fimmu-12-766220-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fd2/8635711/c2ddea7adb69/fimmu-12-766220-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4fd2/8635711/c2ddea7adb69/fimmu-12-766220-g001.jpg

相似文献

1
CAR T-Cell Therapy: Is CD28-CAR Heterodimerization Its Achilles' Heel?嵌合抗原受体（CAR）T细胞疗法：CD28-CAR异源二聚化是其致命弱点吗？
Front Immunol. 2021 Nov 17;12:766220. doi: 10.3389/fimmu.2021.766220. eCollection 2021.
2
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.CD28-跨膜结构域介导嵌合抗原受体与 CD28 的异二聚化。
Front Immunol. 2021 Mar 23;12:639818. doi: 10.3389/fimmu.2021.639818. eCollection 2021.
3
The incidence of cytokine release syndrome and neurotoxicity of CD19 chimeric antigen receptor-T cell therapy in the patient with acute lymphoblastic leukemia and lymphoma.CD19 嵌合抗原受体-T 细胞治疗急性淋巴细胞白血病和淋巴瘤患者细胞因子释放综合征和神经毒性的发生率。
Cytotherapy. 2020 Apr;22(4):214-226. doi: 10.1016/j.jcyt.2020.01.015.
4
Treatment of acute lymphoblastic leukaemia with the second generation of CD19 CAR-T containing either CD28 or 4-1BB.使用第二代包含 CD28 或 4-1BB 的 CD19 CAR-T 治疗急性淋巴细胞白血病。
Br J Haematol. 2018 May;181(3):360-371. doi: 10.1111/bjh.15195. Epub 2018 Apr 10.
5
Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE).三代抗 CD19 嵌合抗原受体 T 细胞融合 TLR2 结构域治疗复发或难治性 B 细胞淋巴瘤：一项 I 期临床试验方案（ENABLE）。
BMJ Open. 2020 Feb 9;10(2):e034629. doi: 10.1136/bmjopen-2019-034629.
6
In Vivo Expansion and Antitumor Activity of Coinfused CD28- and 4-1BB-Engineered CAR-T Cells in Patients with B Cell Leukemia.嵌合抗原受体 T 细胞共转导 CD28 和 4-1BB 基因在 B 细胞白血病患者体内的扩增与抗肿瘤活性。
Mol Ther. 2018 Apr 4;26(4):976-985. doi: 10.1016/j.ymthe.2018.01.022. Epub 2018 Feb 2.
7
Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified (CAR-) T cell therapy.嵌合抗原受体修饰（CAR-）T 细胞治疗后细胞因子释放综合征和神经毒性。
Br J Haematol. 2018 Nov;183(3):364-374. doi: 10.1111/bjh.15644. Epub 2018 Nov 8.
8
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
9
Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.新型含人源可变区的抗 CD19 嵌合抗原受体的功能受铰链和跨膜结构域影响。
Mol Ther. 2017 Nov 1;25(11):2452-2465. doi: 10.1016/j.ymthe.2017.07.013. Epub 2017 Jul 27.
10
Systematic Review and Meta-analysis of CD19-Specific CAR-T Cell Therapy in Relapsed/Refractory Acute Lymphoblastic Leukemia in the Pediatric and Young Adult Population: Safety and Efficacy Outcomes.儿童和青年复发性/难治性急性淋巴细胞白血病中 CD19 特异性嵌合抗原受体 T 细胞治疗的系统评价和荟萃分析：安全性和疗效结局。
Clin Lymphoma Myeloma Leuk. 2021 Apr;21(4):e334-e347. doi: 10.1016/j.clml.2020.12.010. Epub 2020 Dec 17.

引用本文的文献

1
Chimeric anti-HLA antibody receptor engineered human regulatory T cells suppress alloantigen-specific B cells from pre-sensitized transplant recipients.嵌合抗HLA抗体受体工程化人调节性T细胞可抑制预致敏移植受者的同种抗原特异性B细胞。
Front Immunol. 2025 Aug 15;16:1601385. doi: 10.3389/fimmu.2025.1601385. eCollection 2025.
2
The development and application of chimeric antigen receptor natural killer (CAR-NK) cells for cancer therapy: current state, challenges and emerging therapeutic advances.嵌合抗原受体自然杀伤（CAR-NK）细胞在癌症治疗中的开发与应用：现状、挑战及新兴治疗进展
Exp Hematol Oncol. 2024 Dec 4;13(1):118. doi: 10.1186/s40164-024-00583-7.
3

本文引用的文献

1
Efficacy and Safety of CAR-T Cell Products Axicabtagene Ciloleucel, Tisagenlecleucel, and Lisocabtagene Maraleucel for the Treatment of Hematologic Malignancies: A Systematic Review and Meta-Analysis.CAR-T细胞产品阿基仑赛、替雷利珠单抗和利司扑兰治疗血液系统恶性肿瘤的疗效和安全性：系统评价与荟萃分析
Front Oncol. 2021 Jul 26;11:698607. doi: 10.3389/fonc.2021.698607. eCollection 2021.
2
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy.细胞因子释放综合征及癌症免疫治疗相关神经毒性
Nat Rev Immunol. 2022 Feb;22(2):85-96. doi: 10.1038/s41577-021-00547-6. Epub 2021 May 17.
3
The CD28-Transmembrane Domain Mediates Chimeric Antigen Receptor Heterodimerization With CD28.
Transposon-Based Manufacturing of Human CAR-T Cells.
基于转座子的人嵌合抗原受体T细胞制造
Methods Mol Biol. 2024;2748:187-199. doi: 10.1007/978-1-0716-3593-3_14.
4
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil.嵌合抗原受体 T 细胞疗法在三阴性乳腺癌中的应用：追捕无形的恶魔。
Front Immunol. 2022 Nov 22;13:1018786. doi: 10.3389/fimmu.2022.1018786. eCollection 2022.
5
CAR-T cell potency: from structural elements to vector backbone components.嵌合抗原受体T细胞效力：从结构元件到载体骨架组件
Biomark Res. 2022 Sep 19;10(1):70. doi: 10.1186/s40364-022-00417-w.
CD28-跨膜结构域介导嵌合抗原受体与 CD28 的异二聚化。
Front Immunol. 2021 Mar 23;12:639818. doi: 10.3389/fimmu.2021.639818. eCollection 2021.
4
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T Immunotherapies.单细胞分析鉴定出表达 CD19 的脑壁细胞，可能成为 CAR-T 免疫疗法的肿瘤外靶点。
Cell. 2020 Oct 1;183(1):126-142.e17. doi: 10.1016/j.cell.2020.08.022. Epub 2020 Sep 21.
5
The CD28 Transmembrane Domain Contains an Essential Dimerization Motif.CD28 跨膜结构域包含一个必需的二聚化基序。
Front Immunol. 2020 Jul 16;11:1519. doi: 10.3389/fimmu.2020.01519. eCollection 2020.
6
Tuning the Antigen Density Requirement for CAR T-cell Activity.调整 CAR T 细胞活性的抗原密度要求。
Cancer Discov. 2020 May;10(5):702-723. doi: 10.1158/2159-8290.CD-19-0945. Epub 2020 Mar 19.
7
Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma.抗 CD19 CAR T 细胞在 B 细胞淋巴瘤患者中具有完全人源结合结构域的安全性和可行性。
Nat Med. 2020 Feb;26(2):270-280. doi: 10.1038/s41591-019-0737-3. Epub 2020 Jan 20.
8
Parallel Comparison of 4-1BB or CD28 Co-stimulated CD19-Targeted CAR-T Cells for B Cell Non-Hodgkin's Lymphoma.4-1BB或CD28共刺激的靶向CD19的CAR-T细胞治疗B细胞非霍奇金淋巴瘤的平行比较
Mol Ther Oncolytics. 2019 Aug 28;15:60-68. doi: 10.1016/j.omto.2019.08.002. eCollection 2019 Dec 20.
9
Evidence of long-lasting anti-CD19 activity of engrafted CD19 chimeric antigen receptor-modified T cells in a phase I study targeting pediatrics with acute lymphoblastic leukemia.在一项针对小儿急性淋巴细胞白血病的 I 期研究中，证明了移植的嵌合抗原受体修饰的 CD19 特异性 T 细胞具有持久的抗 CD19 活性。
Hematol Oncol. 2019 Dec;37(5):601-608. doi: 10.1002/hon.2672. Epub 2019 Sep 15.
10
An immunoproteomic approach to characterize the CAR interactome and signalosome.一种免疫蛋白质组学方法，用于表征 CAR 相互作用组和信号体。
Sci Signal. 2019 Feb 12;12(568):eaap9777. doi: 10.1126/scisignal.aap9777.